White blood cell telomerase activity and incident respiratory illness among community-dwelling elderly vaccinated against seasonal influenza

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 6, 2007, Pages 694-699

  Targonski, P V ^a,b   Caldwell, C R ^b   Strausbauch, M ^c   Wettstein, P ^c   Poland, G A ^a,b   Tangalos, E G ^b  

^a Mayo Vaccine Research Group   (United States)

^b MAYO CLINIC   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; INFLUENZA VACCINE; RNA; TELOMERASE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; INFLUENZA; INFLUENZA VACCINATION; KAPLAN MEIER METHOD; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RESPIRATORY TRACT INFECTION; VACCINATION REACTION;

AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INCIDENCE; INFLUENZA VACCINES; INFLUENZA, HUMAN; KAPLAN-MEIERS ESTIMATE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MINNESOTA; RESIDENCE CHARACTERISTICS; RESPIRATORY TRACT INFECTIONS; RISK ASSESSMENT; RNA; TELOMERASE;

EID: 36148957878     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100410     Document Type: Article

References (38)

1. World Health Organization. H5N1 avian influenza: first steps towards development of a human vaccine. Wkly. Epidemiol. Rec. 80, 277-278 (2005).
2. Smith, N.M., Bresee, J.S., Shay, D.K., Uyeki, T.M., Cox, N.J. & Strikas, R.A. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices. MMWR 55, 1-42 (2006).
3. World Health Organization. Influenza vaccines. Wkly. Epidemiol. Rec. 80, 279-287 (2005).
4. Minino, A.M., Heron, M.P. & Smith, B.L. Deaths: Preliminary Data for 2004. National Vital Statistics Reports Vol. 54, no. 1 (National Center for Health Statistics, Hyattsville, MD, 2006).
5. Williams, G.O. Vaccines in older patients: combating the risk of mortality. Geriatrics 35, 55-64 (1980).
6. Couch, R.B. Summary of medical literature. Review of effectiveness of inactivated influenza virus vaccine. In Cost-Effectiveness of Influenza Vaccination (ed. Office of Technology Assessment) 43-45 (Office of Technology Assessment, Washington, DC, 1981).
7. Gross, P.A., Hermogenes, A.W., Sacks, H.S., Lau, J. & Levandowski, R.A. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann. Intern. Med. 123, 518-527 (1995).
8. Webster, R.G. Immunity to influenza in the elderly. Vaccine 18, 1686-1689 (2000).
9. Keitel, W.A. et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch. Intern. Med. 166, 1121-1127 (2006).
10. Targonski, P.V. & Poland, G.A. Intranasal cold-adapted influenza virus vaccine combined with inactivated virus vaccines: that extra boost for the elderly? Drugs & Aging 21, 349-359 (2004).
11. Pawelec, G., Ouyand, Q., Colonna-Romano, G., Candore, G., Lio, D. & Caruso, C. Is human immunosenescence clinically relevant? Looking for "immunological risk phenotypes". Trends Immunol. 23, 330 (2002).
12. Ouyang, Q., Wagner, W.M., Wikby, A., Remarque, E. & Pawelec, G. Compromised IFN-gamma production in the elderly leads to both acute and latent viral antigen stimulation: contribution to the immune risk phenotype? Eur. Cytokine Netw. 13, 392-394 (2002).
13. Wikby, A. et al. The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech. Ageing Dev. 127, 695-704 (2006).
14. Goronzy, J.J., Fulbright, J.W., Crowson, C.S., Poland, G.A., O'Fallon, W.M. & Weyand, C.M. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J. Virol. 75, 12182-12187 (2001).
15. - T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J. Immunol. 168, 5893-5899 (2002).
16. Trzonkowski, P. et al. Association between cytomegalovirus infection, enhanced proinflammatory response, and low level of anti-hemagglutinins during the anti-influenza vaccination - an impact of immunosenescence. Vaccine 21, 3826-3836 (2003).
17. + T-cell replicative senescence in human aging. Immunol. Rev. 205, 147-157 (2005).
18. Weng, N.P., Levine, B.L., June, C.H. & Hodes, R.J. Regulated expression of telomerase activity in human T lymphocyte development and activation. J. Exp. Med. 183, 2471-2479 (1996).
19. Campisi, J., Kim, S.H., Lim, C.S. & Rubio, M. Cellular senescence, cancer and aging: the telomere connection. Exp. Gerontol. 36, 1619-1637 (2001).
20. Harley, C., Futcher, A.B. & Greider, C. Telomeres shorten during ageing of human fibroblasts. Nature 345, 458-460 (1990).
21. Cawthon, R.M., Smith, K.R., O'Brien, E., Sivatchenko, A. & Kerber, R.A. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 361, 393-395 (2003).
22. Effros, R.B. Role of T lymphocyte replicative senescence in vaccine efficacy. Vaccine 25, 599-604 (2007).
23. + counterparts. J. Immunol. 156, 3587-3590 (1996).
24. Goodwin, K., Viboud, C. & Simonsen, L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24, 1159-1169 (2006).
25. Hobson, D., Curry, R.L., Beare, A.S. & Ward-Gardner, A. The role of serum hemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.) 70, 767-777 (1972).
26. Govaert, T.M., Sprenger, M.J., Dinant, G.J., Aretz, K., Masurel, N. & Knottnerus, J.A. Immune response to influenza vaccination of elderly people: a randomized double-blind placebo-controlled clinical trial. Vaccine 12, 1185-1189 (1994).
27. Gravenstein, S. et al. Efficacy of an influenza hemaglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J. Am. Geriatr. Soc. 42, 245-251 (1994).
28. Murasko, D.M. et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp. Gerontol. 37, 427-439 (2002).
29. McElhaney, J.E. et al. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol. 176, 6333-6339 (2006).
30. Bodnar, A.G., Kim, N.W., Effros, R.B. & Chiu, C.P. Mechanism of telomerase induction during T cell activation. Exp. Cell Res. 228, 58-64 (1996).
31. Kendal, A.P., Periera, M.S. & Skehel, J.J. Concepts and Procedures for Laboratory-Based Influenza Surveillance: The Hemagglutination Inhibition Test for Influenza Viruses (Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta) 17-35 (1982).
32. Gravenstein, S. et al. Efficacy of an influenza hemagluttinin-diptheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J. Am. Geriatr. Soc. 42, 245-251 (1994).
33. European Agency for the Evaluation of Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96), 12 March 1997.
34. Bieche, I. et al. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin. Cancer Res. 6, 452-459 (2000).
35. Heid, C.A. Stevens, J., Livak K.J. & Williams, P.M. Real time quantitative PCR. Genome Res. 6, 986-994 (1996).
36. Gibson, U.E.M., Heid, C.A. & Williams, P.M. A novel method for real time quantitative RT-PCR. Genome Res. 6, 995-1001 (1996).
37. Centers for Disease Control and Prevention. Flu activity: reports and surveillance methods in the United States 〈http://www.cdc.gov/flu/weekly/ fluactivity.htm〉. Date accessed.
38. Melton, L.J. III. History of the Rochester Epidemiology Project. Mayo Clinic. Proc. 71, 266-274 (1996).